Medshine Discovery Inc. has presented benzylamino tricyclic compounds acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.
Dana-Farber Cancer Institute Inc. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to an anaplastic lymphoma kinase (ALK)-targeting moiety through a linker reported to be useful for the treatment of cancer.
Medshine Discovery Inc. has synthesized dimethyl-substituted thiazololactam compounds acting as mitogen-activated protein kinase 3 (MAPK3; ERK1) and/or (MAPK1; ERK2) inhibitors reported to be useful for the treatment of cancer.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has described pyrimidine and nitrogen-containing 6-membered aromatic heterocyclic compounds acting as S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
Aptevo Therapeutics Inc. has filed a provisional patent with the U.S. Patent and Trademark Office (USPTO) pertaining to an anti-PD-L1 x anti-CD40 bispecific antibody, APVO-711, with the potential to treat a range of solid malignancies such as head and neck squamous cell carcinoma, melanoma and carcinomas of the lung, gastrointestinal tract and colon.
Transcode Therapeutics Inc. has received clearance from the FDA to proceed with a first-in-human phase 0 trial of TTX-MC138 in cancer patients with advanced solid tumors. A single dose of radiolabeled TTX-MC138 will be followed by noninvasive PET-MRI to quantify the amount of radiolabeled TTX-MC138 delivered to metastatic lesions.
Astex Therapeutics Ltd. and Taiho Pharmaceutical Co. Ltd. have divulged GTPase KRAS (G12C mutant), (G12D mutant) and/or (G12V mutant) inhibitors reported to be useful for the treatment of cancer.
Medshine Discovery Inc. has divulged benzospiroheterocyclic derivatives acting as prostaglandin E receptor 4 (PTGER4; EP4 receptor) antagonists reported to be useful for the treatment of cancer.
